1. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
- Author
-
Toshihiro Wajima, Roger Echols, Nao Kawaguchi, and Takayuki Katsube
- Subjects
medicine.medical_specialty ,bloodstream infections ,medicine.drug_class ,Urinary system ,Cephalosporin ,Population ,cephalosporin ,Renal function ,Siderophores ,Bacteremia ,Microbial Sensitivity Tests ,Gastroenterology ,complicated urinary tract infection ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,population pharmacokinetics ,Internal medicine ,cefiderocol ,pharmacodynamics ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,education ,Pharmacology ,0303 health sciences ,education.field_of_study ,030306 microbiology ,business.industry ,ventilation ,Pneumonia ,medicine.disease ,Anti-Bacterial Agents ,Cephalosporins ,Infectious Diseases ,Pharmacodynamics ,Urinary Tract Infections ,business ,augmented renal function - Abstract
Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 hours infusion in patients with creatinine clearance (CrCL) of 60 to 119 ml/min, and it is adjusted for patients with, Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 hours infusion in patients with creatinine clearance (CrCL) of 60 to 119 ml/min, and it is adjusted for patients with MIC) was 100% in most of the enrolled patients. The probability of target attainment (PTA) for 100% fT>MIC was >90% against MICs of ≤4 μg/ml for all infection sites and renal function groups except for BSI/sepsis patients with normal renal function (85%). These study results support adequate plasma exposure can be achieved at the cefiderocol recommended dosing regimen for the infected patients, including the patients with augmented renal function, ventilation, and/or severe illness.
- Published
- 2021